专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

CA2960387A1 MIR-29 MIMICS AND USES THEREOF 未知
公开(公告)号：CA2960387A1
公开(公告)日：2016-03-17
申请号：CA2960387
申请日：2015-09-08
申请人： MIRAGEN THERAPEUTICS INC
发明人： MONTGOMERY RUSTY L , DALBY CHRISTINA , VAN ROOIJ EVA , GALLANT-BEHM CORRIE
IPC分类号： C07H21/02
摘要： The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.

12. 发明专利

AU2013278011A1 Oligonucleotide-based inhibitors comprising locked nucleic acid motif 未知
公开(公告)号：AU2013278011A1
公开(公告)日：2015-01-15
申请号：AU2013278011
申请日：2013-06-21
申请人： MIRAGEN THERAPEUTICS INC
发明人： VAN ROOIJ EVA , DALBY CHRISTINA M , MONTGOMERY RUSTY L
IPC分类号： C12N15/113 , A61K31/7115 , A61K48/00
摘要： The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.

13. 发明专利

RU2712511C2 МИМЕТИКИ MIR-29 И ПУТИ ИХ ПРИМЕНЕНИЯ 未知
公开(公告)号：RU2712511C2
公开(公告)日：2020-01-29
申请号：RU2017111775
申请日：2015-09-08
申请人： MIRAGEN THERAPEUTICS INC
发明人： MONTGOMERY RUSTY L , DALBY CHRISTINA , VAN ROOIJ EVA , GALLANT-BEHM CORRIE
IPC分类号： A61K31/70 , C07H21/02
摘要： Изобретениеотноситсяк областибиотехнологии. Описанагруппаизобретений, включающаясоединение, представляющеемиметик miR-29, фармацевтическуюкомпозициюдлямодулирования miR-29, содержащуювышеуказанноесоединение, способрегуляциигенавнеклеточногоматриксав клетке, включающийприведениеклеткив контактс вышеуказаннымсоединением, способлеченияилипредупрежденияфиброзатканиу субъекта, нуждающегосяв этом, включающийвведениесубъектувышеуказанногосоединенияилифармацевтическойкомпозиции, способоценкиэффективностилечениясоединением, включающийопределениеуровняэкспрессииодногоилиболеегеновв клеткахилифибрознойтканисубъектадолечениясоединением. Изобретениерасширяетарсеналсредств, представляющихсобоймиметики miR-29. 5 н. и 18 з.п. ф-лы, 14 ил., 5 табл., 7 пр.

14. 发明专利

NZ728207A Oligonucleotide-based inhibitors comprising locked nucleic acid motif 未知
公开(公告)号：NZ728207A
公开(公告)日：2018-09-28
申请号：NZ72820713
申请日：2013-06-21
申请人： MIRAGEN THERAPEUTICS INC
发明人： VAN ROOIJ EVA , DALBY CHRISTINA M , MONTGOMERY RUSTY L
IPC分类号： C12N15/113 , A61K31/7115 , A61K48/00
摘要： The present invention relates to chemical modification motifs for oligonucleotides complementary to miR-92a. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.

15. 发明专利

HK1244509A1 包含鎖核酸基序的基於寡核苷酸的抑制劑未知
公开(公告)号：HK1244509A1
公开(公告)日：2018-08-10
申请号：HK18103977
申请日：2018-03-22
申请人： MIRAGEN THERAPEUTICS INC
发明人： VAN ROOIJ EVA , DALBY CHRISTINA M , MONTGOMERY RUSTY L
IPC分类号： C12N20060101 , A61K20060101 , A61P20060101

16. 发明专利

PH12017500424B1 MIR-29 MIMICS AND USES THEREOF 未知
公开(公告)号：PH12017500424B1
公开(公告)日：2017-07-17
申请号：PH12017500424
申请日：2017-03-07
申请人： MIRAGEN THERAPEUTICS INC
发明人： MONTGOMERY RUSTY L , DALBY CHRISTINA , VAN ROOIJ EVA , GALLANT-BEHM CORRIE
IPC分类号： C07H21/02
摘要： The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.

17. 发明专利

AU2015315298A1 miR-29 mimics and uses thereof 未知
公开(公告)号：AU2015315298A1
公开(公告)日：2017-03-30
申请号：AU2015315298
申请日：2015-09-08
申请人： MIRAGEN THERAPEUTICS INC
发明人： MONTGOMERY RUSTY L , DALBY CHRISTINA , VAN ROOIJ EVA , GALLANT-BEHM CORRIE
IPC分类号： C07H21/02
摘要： The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.

18. 发明专利

HK1209781A1 OLIGONUCLEOTIDE-BASED INHIBITORS COMPRISING LOCKED NUCLEIC ACID MOTIF 未知
公开(公告)号：HK1209781A1
公开(公告)日：2016-04-08
申请号：HK15110337
申请日：2015-10-21
申请人： MIRAGEN THERAPEUTICS INC
发明人： ROOIJ EVA VAN , DALBY CHRISTINA M , MONTGOMERY RUSTY L
IPC分类号： C12N20060101 , A61K20060101
摘要： The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式